Taro Trials First Patented Medicine

Israeli drugmaker Taro Pharmaceuticals has announced that its first branded product for the treatment of essential tremors has received an FDA Investigational New Drug exemption. Early phase clinical trials of the medicines, called T-2000, (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid) have been promising, particularly when the drug was used in conjunction with an existing treatment, propranolol.

To read the full article, please choose one of the following options: